GRAFTECH INTERNATIONAL LTD
For the period ended Jun 30, 2025. Filed Jul 25, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to the Condensed Consolidated Financial Statements (unaudited)
(1)Organization and Summary of Significant Accounting Policies
A. Organization
GrafTech International Ltd. (the “Company” or “GrafTech”) is a leading manufacturer of high-quality graphite electrode products essential to the production of electric arc furnace (“EAF”) steel and other ferrous and non-ferrous metals. References herein to “GTI,” “we,” “our,” or “us” refer collectively to the Company and its subsidiaries. The Company’s common stock is listed on the NYSE under the symbol “EAF.”
The Company’s only reportable segment, Industrial Materials, is comprised of itstwo major product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is our key raw material used in the production of graphite electrodes. The Company’s vision is to provide highly engineered graphite electrode products, services and solutions to EAF operators.
B. Basis of Presentation
The interim condensed consolidated financial statements are unaudited; however, in the opinion of management, they have been prepared in accordance with Rule 10-01 of Regulation S-X and in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The December 31, 2024 Consolidated Balance Sheet data included herein was derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K, but does not include all disclosures required by GAAP in audited financial statements. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, including the accompanying notes, contained in the Company’s Annual Report on Form 10-K.
The unaudited condensed consolidated financial statements reflect all adjustments (all of which are of a normal, recurring nature) which management considers necessary for a fair presentation of our financial statements for the interim periods presented. The results for the interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year.
Certain prior period amounts within net cash used in operating activities have been reclassified to conform to the current period presentation. These reclassifications did not impact net cash used in operating activities in total.
C. New Accounting Standards
Recently Adopted Accounting Standards
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The adoption of this ASU did not have a material impact on our consolidated financial statements and related disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to enhance the transparency, decision usefulness and effectiveness of income tax disclosures. The amendments in this ASU require a public entity to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. A public entity is also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The amendments also remove certain disclosures that are no longer considered cost beneficial. The amendments are effective prospectively for annual periods beginning after December 15, 2024. Adoption of this ASU will result in additional disclosure in our Annual Report on Form 10-K for the year ended December 31, 2025 but will not impact our consolidated financial position, results of operations or cash flows.
Recently Issued Accounting Pronouncements Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. Under this ASU, a public entity would be required to disclose information about purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depletion for each income statement line item that contains those expenses. This ASU is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. This ASU allows for early adoption and requires either prospective adoption to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently assessing the impact of this ASU on its financial statements and disclosures, but does not expect it to be material.
(2)Revenue from Contracts with Customers
Disaggregation of Revenue
The following table provides information about disaggregated revenue by type of product:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Dollars in thousands) | ||||
| Graphite Electrodes | $119,440 | $124,807 | $220,702 | $248,794 |
| By-products and other | 12,400 | 12,520 | 22,977 | 25,117 |
| Total Revenues | $131,840 | $137,327 | $243,679 | $273,911 |
In the first quarter of 2025, the Company updated its presentation of disaggregated revenue to align with how management evaluates its top-line commercial and financial performance. Due to the immaterial amount of remaining take or pay contracts with initial terms ofthree tofive years (“LTAs”), we no longer show these revenues as a separate line item.
Contract Balances
Substantially all of the Company’s receivables relate to contracts with customers. Accounts receivables are recorded when the right to consideration becomes unconditional. Payment terms on invoices range from 20 to 180 days depending on the customary business practices of the jurisdictions in which we do business.
We didnot have any contract asset balances as of June 30, 2025 or December 31, 2024.
Deferred revenue is recorded for consideration received from customers in advance of satisfaction of the related performance obligations.
Deferred revenue is included in “Other accrued liabilities” on the Condensed Consolidated Balance Sheets. The timing of revenue recognition, billings, and cash collections resulted in a deferred revenue balance of $11.2 million as of June 30, 2025 and December 31, 2024.
(3)Segment Reporting
Our Industrial Materials segment, our only operating and reportable segment, manufactures high-quality graphite electrodes essential to the production of EAF steel and other ferrous and non-ferrous metals. Petroleum needle coke, a crystalline form of carbon derived from decant oil, is a key raw material used in the production of graphite electrodes. We utilize the majority of the needle coke that we produce internally to manufacture our graphite electrodes and as a result over 90% of our revenues from external customers are derived from the sale of graphite electrodes.
Our chief operating decision maker is our chief executive officer. The chief operating decision maker assesses performance for our Industrial Materials segment and decides how to allocate resources based on net income or losses, which are reported on the Condensed Consolidated Statements of Operations and Comprehensive Loss.
The chief operating decision maker uses net loss to evaluate growth trends, establish budgets, assess operational efficiencies and evaluate our overall financial performance.
The following table presents selected financial information with respect to the Company’s single operating segment for the three and six months ended June 30, 2025 and 2024, respectively:
| Three Months EndedJune 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Dollars in thousands) | ||||
| Net sales | $131,840 | $137,327 | $243,679 | $273,911 |
| Cash cost of goods sold(1) | 107,354 | 110,021 | 197,560 | 220,763 |
| Other segment expenses | 22,531 | 21,949 | 43,090 | 46,411 |
| Lower of cost or market inventory valuation adjustment | 1,893 | 1,381 | 4,676 | 4,073 |
| Research and development | 1,348 | 1,447 | 3,227 | 3,074 |
| Selling and administrative expenses | 13,267 | 5,098 | 27,889 | 20,375 |
| Rationalization expenses | — | 110 | — | 3,255 |
| Other income, net | (2,426) | (1,091) | (1,979) | (1,484) |
| Interest expense | 25,418 | 15,609 | 55,259 | 31,235 |
| Interest income | (1,866) | (1,853) | (3,801) | (3,377) |
| Income tax expense (benefit) | 51,207 | (592) | 43,995 | (4,793) |
| Net loss | $(86,886) | $(14,752) | $(126,237) | $(45,621) |
(1)Cash cost of goods sold is defined as cost of goods sold less depreciation and amortization and less cost of goods sold associated with the portion of our sales that consist of deliveries of by-products of the manufacturing processes, and is the significant expense the chief operating decision maker uses to evaluate segment expenses.
(4)Intangible Assets
The following table summarizes intangible assets with determinable useful lives by major category, which are included in “Other assets” on our Condensed Consolidated Balance Sheets:
| June 30, 2025 | December 31, 2024 | |||||
|---|---|---|---|---|---|---|
| GrossCarryingAmount | AccumulatedAmortization | NetCarryingAmount | GrossCarryingAmount | AccumulatedAmortization | NetCarryingAmount | |
| (Dollars in thousands) | ||||||
| Trade names | $22,500 | $(18,628) | $3,872 | $22,500 | $(18,226) | $4,274 |
| Technology | 55,300 | (49,886) | 5,414 | 55,300 | (48,613) | 6,687 |
| Customer relationships | 64,500 | (43,184) | 21,316 | 64,500 | (41,063) | 23,437 |
| Total finite-lived intangible assets | $142,300 | $(111,698) | $30,602 | $142,300 | $(107,902) | $34,398 |
Amortization expense for intangible assets was $1.9 million and $2.1 million for the three months ended June 30, 2025 and 2024, respectively, and $3.8 million and $4.1 million for the six months ended June 30, 2025 and 2024, respectively. Amortization expense is expected to be approximately $3.5 million for the remainder of 2025, $6.7 million in 2026, $6.1 million in 2027, $5.5 million in 2028, $4.9 million in 2029 and $2.9 million in 2030.
(5)Debt and Liquidity
The following table presents our long-term debt:
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Dollars in thousands) | ||
| Initial First Lien Term Loans due 2029 | 175,000 | 175,000 |
| Existing 4.625% Senior Notes due 2028 | 1,755 | 1,755 |
| New 4.625% Second Lien Notes due 2029 | 498,245 | 498,245 |
| Existing 9.875% Senior Notes due 2028 | 3,833 | 3,833 |
| New 9.875% Second Lien Notes due 2029 | 446,167 | 446,167 |
| Unamortized debt discount and issuance costs | (34,189) | (38,085) |
| Total long-term debt | $1,090,811 | $1,086,915 |
The fair value of our debt was approximately $875.6 million and $905.8 million as of June 30, 2025 and December 31, 2024, respectively. The fair values were determined using Level 1 quoted market prices for the same or similar debt instruments.
Initial First Lien Term Loan Facility; Delayed Draw First Lien Term Loan Facility
As of June 30, 2025 and December 31, 2024, we did not have any borrowings under our Delayed Draw First Lien Term Loan Facility, with $100 million available as of the end of each period.
2018 Term Loan and 2018 Revolving Credit Facility
As of June 30, 2025 and December 31, 2024, the availability under our 2018 Revolving Credit Facility was $108.0 million. As any borrowings under the 2018 Revolving Credit Facility remain subject to compliance with the financial covenant thereunder, our operating performance as of June 30, 2025 and December 31, 2024 resulted in our inability to access the full amount of commitments under the facility. As of June 30, 2025 and December 31, 2024, there wereno borrowings outstanding on the 2018 Revolving Credit Facility and there was $7.4 million of letters of credit drawn against the 2018 Revolving Credit Facility.
As of June 30, 2025 and December 31, 2024, there wereno outstanding term loans under the 2018 Term Loan Facility.
We were in compliance with all of our debt covenants as of June 30, 2025 and December 31, 2024.
(6)Inventories
Inventories are comprised of the following:
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Dollars in thousands) | ||
| Inventories: | ||
| Raw materials and supplies | $89,721 | $78,386 |
| Work in process | 136,039 | 122,590 |
| Finished goods | 30,166 | 30,265 |
| Total | $255,926 | $231,241 |
In the second quarter and first six months of 2025, we recorded lower of cost or market (“LCM”) inventory valuation adjustments of $1.9 million and $4.7 million, respectively, in order to state our inventories at the lower of cost or market.
(7)Interest Expense
The following table presents the components of interest expense:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Dollars in thousands) | ||||
| Interest incurred on debt | $22,539 | $17,110 | $45,071 | $34,205 |
| Accretion of original issue discount | 1,260 | 521 | 2,527 | 1,041 |
| Amortization of debt issuance costs | 688 | 749 | 1,369 | 1,497 |
| Debt modification costs | 931 | — | 6,292 | — |
| Amortization of interest rate swap deferred gains | — | (2,771) | — | (5,508) |
| Total interest expense | $25,418 | $15,609 | $55,259 | $31,235 |
The financing transactions entered into in 2024 were accounted for as a modification of the existing debt under ASC 470-50, Debt—Modifications and Extinguishments.
The Company incurred $0.9 million and $6.3 million of fees and expenses related to post-closure costs attributable to the modification, which were expensed as incurred in the second quarter and first six months of 2025, respectively, and are included in Interest expense on the Condensed Consolidated Statements of Operations.
The Existing 9.875% Notes and the New 9.875% Notes carry fixed interest rates of 9.875%. The Existing 4.625% Notes and the New 4.625% Notes carry fixed interest rates of 4.625%. The Initial First Lien Term Loan had an effective interest rate of 10.32% as of June 30, 2025.
See Note 5, “Debt and Liquidity” for details of our debt.
(8)Commitments and Contingencies
Legal Proceedings
We are involved in various investigations, lawsuits, claims, demands, labor disputes and other legal proceedings, including with respect to environmental and human exposure or other personal injury matters, arising out of or incidental to the conduct of our business. While it is not possible to determine the ultimate disposition of each of these matters and proceedings, we do not believe that their ultimate disposition will have a material adverse effect on our financial position, results of operations or cash flows. Additionally, we are involved in the following legal proceedings:
Brazil Clause IV
Pending litigation in Brazil has been brought by employees seeking to recover additional amounts and interest thereon under certain wage increase provisions applicable in 1989 and 1990 under collective bargaining agreements to which employers in the Bahia region of Brazil were a party (including our subsidiary in Brazil). Companies in Brazil have settled claims arising out of these provisions and, in May 2015, the litigation was remanded by the Brazilian Supreme Court in favor of the employees union. After denying an interim appeal by the Bahia region employers on June 26, 2019, the Brazilian Supreme Court finally ruled in favor of the employees union on September 26, 2019. The employers union has determined not to seek annulment of such decision. Separately, on October 1, 2015, a related action was filed by current and former employees against our subsidiary in Brazil to recover amounts under such provisions, plus interest thereon, which amounts together with interest could be material to us. If the Brazilian Supreme Court proceeding above had been determined in favor of the employers union, it would also have resolved this proceeding in our favor. In the first quarter of 2017, the state court initially ruled in favor of the employees. We appealed this state court ruling, and the appellate court issued a decision in our favor on May 19, 2020. The employees have further appealed and, on December 16, 2020, the court upheld the decision in favor of GrafTech Brazil. On February 22, 2021, the employees filed a further appeal and, on April 28, 2021, the court rejected the employees’ appeal in favor of GrafTech Brazil. The employees filed a further appeal and on September 12, 2022, we filed our response in opposition. We intend to vigorously defend our position. As of June 30, 2025, we are unable to assess the potential loss associated with these proceedings as the claims do not currently specify the number of employees seeking damages or the amount of damages being sought.
Securities and Derivative Litigation
On January 25, 2024, a stockholder of the Company filed a class action complaint on behalf of a putative class consisting of purchasers of GrafTech common stock between February 8, 2019 and August 3, 2023 in the United States District Court for the Northern District of Ohio. The complaint names the Company, certain past and present executive officers, and three entities associated with Brookfield Corporation and its affiliates (together, “Brookfield”) as defendants. The complaint alleges that certain public filings and statements made by the Company contained material misrepresentations or omissions relating to the circumstances before and after the prior temporary suspension of the Company’s graphite electrode facility located in Monterrey, Mexico, in September 2022. The complaint seeks unspecified compensatory damages, costs and expenses, and unspecified equitable or injunctive relief. On May 15, 2024, the Court appointed the University of Puerto Rico Retirement System as the lead plaintiff. On October 7, 2024, the plaintiff filed an amended complaint. The defendants have moved to dismiss the complaint.
Beginning on June 9, 2025, stockholders filed three derivative actions purporting to assert claims on behalf of and in the name of the Company in the U.S. District Court for the Northern District of Ohio, against certain past and present directors and officers of the Company and three entities associated with Brookfield. The complaints generally allege breaches of fiduciary duty and mismanagement based on the same facts and circumstances alleged in the securities class action lawsuit described above, and seek an award to the Company of unspecified damages, costs, expenses, and equitable relief.
At this stage of the proceedings, it is too early to determine if any of these matters would reasonably be expected to have a material adverse effect on our financial condition.
Tax Receivable Agreement
On April 23, 2018, the Company entered into the tax receivable agreement (“Tax Receivable Agreement”) that provides Brookfield as the sole stockholder prior to the Company’s initial public offering in April 2018 (the “IPO”), the right to receive future payments from us for 85% of the amount of cash savings, if any, in U.S. federal income tax and Swiss tax that we and our subsidiaries realize as a result of the utilization of the pre-IPO tax assets. In addition, we will pay interest on the payments we will make to Brookfield with respect to the amount of these cash savings from the due date (without extensions) of our tax return where we realize these savings to the payment date. On April 10, 2023, the Tax Receivable Agreement was amended and restated to change the applicable interest rate from LIBOR plus 1.00% per year to the one-month period secured overnight financing rate administered by the Federal Reserve Bank of New York plus 1.10%. The term of the Tax Receivable Agreement commenced on April 23, 2018 and will continue until there is no potential for any future tax benefit payments.
In the second quarter of 2025, we recorded a full valuation allowance against our U.S. deferred tax assets as it is more likely than not that we will not be able to utilize U.S. deferred tax assets. These deferred taxes include the remaining pre-IPO tax assets covered by the Tax Receivable Agreement for which the related foreign tax credits are more likely than not to expire prior to being utilized. As a result, the remaining $3.8 million Tax Receivable Agreement liability was written off to Other income, net in the Condensed Consolidated Financial Statements.
Brazil Income Tax Audit
On October 23, 2024, GrafTech Brasil Participações Ltda. received an income tax assessment notice from the Brazilian Internal Revenue Service (“IRS”) totaling approximately $32.6 million including approximately $19.4 million of interest and penalties, resulting from an audit carried out between 2023 and 2024, related to the period from 2019 to 2020. In this assessment, two issues were raised by the tax auditor. The first item disallowed the investment tax incentive (75% reduction of income tax), under the allegation that the Company did not have a negative tax debt certificate. The second disallowed the use of the VAT benefit (called Desenvolve) to increase the investment tax incentive. The Company believes that the IRS assessment is incorrect and does not believe that it is probable that it will incur a loss related to these matters. The Company intends to vigorously defend its position regarding both items.
(9)Income Taxes
We compute and apply to ordinary income or loss an estimated annual effective tax rate on a quarterly basis based on current and forecasted business levels and activities, including the mix of domestic and foreign results and enacted tax laws. The estimated annual effective tax rate is updated quarterly based on actual results and updated operating forecasts. Ordinary income or loss refers to income or loss before income taxes excluding significant, unusual or infrequently occurring items. The tax effect of an unusual or infrequently occurring item is recorded in the interim period in which it occurs as a discrete item of tax.
The following table summarizes the income tax benefit:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Dollars in thousands) | ||||
| Income tax expense (benefit) | $51,207 | $(592) | $43,995 | $(4,793) |
| Loss before income taxes | (35,679) | (15,344) | (82,242) | (50,414) |
| Effective tax rate | (143.5)% | 3.9% | (53.5)% | 9.5% |
The effective tax rate for the second quarter and first six months of 2025 was different than the U.S. statutory tax rate of 21% primarily due to the recording of a valuation allowance against the Company’s previously realizable U.S. and Switzerland deferred tax assets of $34.2 million and $8.4 million, respectively, as described below. The effective tax rate for the second quarter and first six months of 2024 was different from the U.S. statutory rate of 21% primarily due to the mix of U.S. and foreign earnings, tax incentives and provisions of the Tax Cuts and Jobs Act of 2017 (the “Tax Cuts and Jobs Act”).
We file income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. All U.S. federal tax years prior to 2021 are generally closed by statute or have been audited and settled with the applicable domestic tax authorities. Other jurisdictions are generally closed for years prior to 2019.
At each reporting period, the Company assesses the need for valuation allowances against deferred tax assets and whether it is more likely than not that deferred tax benefits will be realized in each jurisdiction. Consideration is given to all available evidence, both positive and negative, in assessing the need for a valuation allowance. Examples of positive evidence include a strong earnings history, an event or events that would increase the Company's taxable income or reduce expenses, or tax planning strategies that would create the ability to realize deferred tax assets. Examples of negative evidence include cumulative losses in recent years or a history of tax attributes expiring unused. In circumstances where the negative evidence outweighs the positive evidence, the Company has established or maintained valuation allowances on the jurisdiction’s net deferred tax assets. However, the recognition of the valuation allowance does not limit the Company's ability to utilize these tax assets on a tax return in the future should taxable income be realized in sufficient amount to realize the assets.
At the end of the second quarter of 2025, the Company’s cumulative losses in the U.S. and Switzerland in recent years, when assessed with other positive and negative evidence, represented sufficient negative evidence to require full valuation allowances on its U.S. and Switzerland previously realizable deferred tax assets. As of June 30, 2025, the Company’s U.S. and Switzerland operations had valuation allowances recorded of $52.4 million and $8.4 million, respectively.
On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”), containing various changes to U.S. corporate tax laws was enacted. Following enactment, we have assessed the applicability of the retroactive business provisions in the OBBBA. We are still evaluating the potential future impact of the OBBBA on our consolidated financial statements.
(10)Fair Value Measurements and Derivative Instruments
In the normal course of business, we are exposed to certain risks related to fluctuations in currency exchange rates, commodity prices and interest rates. We use various derivative financial instruments, primarily foreign currency derivatives, commodity derivative contracts, and interest rate swaps as part of our overall strategy to manage risks from these market fluctuations.
Since the counterparties to these financial instruments are large commercial banks and similar financial institutions, we do not believe that we are exposed to material counterparty credit risk. We do not anticipate nonperformance by any of the counterparties to our instruments.
Foreign currency derivatives
We enter into foreign currency derivatives from time to time to attempt to manage exposure to changes in currency exchange rates. These foreign currency instruments, which include, but are not limited to, forward exchange contracts and purchased currency options, are used to hedge global currency exposures such as foreign currency denominated debt, receivables, payables, sales and purchases.
Foreign currency forward and swap contracts are used to mitigate the foreign exchange risk of balance sheet items. These derivatives are fair value hedges. Gains and losses from these derivatives are recorded in cost of goods sold and they are largely offset by the financial impact of translating foreign currency-denominated payables and receivables.
In the second quarter of 2025, we entered into foreign currency derivatives with maturities ofone month to 12 months in order to protect against the risk that cash flows associated with certain sales and purchases denominated in a currency other than the U.S. dollar will be adversely affected by future changes in foreign exchange rates. These derivatives are designated as cash flow hedges. The resulting unrealized gains or losses from these derivatives are recorded in AOCL and subsequently, when realized, are reclassified to net sales or cost of goods sold in the Condensed Consolidated Statements of Operations when the hedged exposures affect earnings.
Commodity derivative contracts
From time to time, we enter into commodity derivative contracts for refined oil products. These contracts are entered into to protect against the risk that eventual cash flows related to these products will be adversely affected by future changes in prices. The unrealized gains or losses related to commodity derivative contracts designated as cash flow hedges are recorded in AOCL and subsequently, when realized, are reclassified to the Condensed Consolidated Statement of Operations when the hedged item impacts earnings, which is when the finished product is sold.
Interest rate swap contracts
We have utilized interest rate swaps in the past to limit exposure to market fluctuations on our variable-rate debt. For each derivative agreement that is designated as a cash-flow hedge, the unrealized gain or loss is recorded in AOCL and, when realized, is recorded to interest expense. Upon discontinuance of a designated cash-flow hedging relationship, when interest payments are still probable of occurring, the fair value at the date of discontinuance is deferred into AOCL and amortized into interest expense based upon the term of the cash-flow hedging relationship.
All derivatives are recorded on the balance sheet at fair value. If the derivative is designated and effective as a cash flow hedge, changes in the fair value of the derivative are recognized in AOCL until the hedged item is recognized in earnings. The ineffective portion of a derivative's fair value, if any, is recognized in earnings immediately. If a derivative is not a hedge, changes in the fair value are adjusted through earnings. The fair values of the outstanding derivatives are recorded on the balance sheet as assets (if the derivatives are in a gain position) or liabilities (if the derivatives are in a loss position). The fair values will also be classified as short-term or long-term depending upon their maturity dates. The fair value of all of our derivatives was determined using Level 2 inputs.
The notional amounts of our outstanding derivative instruments as of June 30, 2025 and December 31, 2024 were as follows:
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Notional Amount | Notional Amount | |
| (Dollars in thousands) | ||
| Derivative instruments designated as hedges: | ||
| Foreign currency derivatives | $5,740 | $— |
| Derivative instruments not designated as hedges: | ||
| Foreign currency derivatives | $24,059 | $11,918 |
The fair value of our outstanding derivatives designated as hedges was a pre-tax unrealized gain $0.1 million as of June 30, 2025, which was recorded in prepaid and other current assets on the Condensed Consolidated Balance Sheets.
As of June 30, 2025, net realized pre-tax gains of $0.1 million related to our foreign currency derivatives were reported in AOCL and will be released to earnings within the next 12 months. No ineffectiveness expense was recorded in the second quarter or first six months of 2025 or 2024.
The pre-tax realized (gains) losses on designated cash flow hedges are recognized in the Statements of Operations when the hedged item impacts earnings and were as follows for the periods ended June 30, 2025 and 2024:
| Amount of (Gain) LossRecognized | |||
|---|---|---|---|
| Location of Realized (Gain) Loss Recognized in the Condensed Consolidated Statement of Operations · Three Months Ended June 30, | |||
| 2025 · 2024 | |||
| Derivatives designated as cash flow hedges: · (Dollars in thousands) | |||
| Foreign currency derivatives | Cost of goods sold | $(188) | $423 |
| Interest rate swap contracts | Interest expense | — | (2,771) |
| Amount of (Gain)/LossRecognized | |||
| Location of Realized (Gain)/Loss Recognized in the Condensed Consolidated Statement of Operations · Six Months Ended June 30, | |||
| 2025 · 2024 | |||
| Derivatives designated as cash flow hedges: | (Dollars in thousands) | ||
| Foreign currency derivatives | Cost of goods sold | $(245) | $355 |
| Commodity derivative contracts | Cost of goods sold | — | (2,462) |
| Interest rate swap contracts | Interest expense | — | (5,508) |
Pretax gains and losses on non-designated derivatives recognized in earnings were as follows:
| Amount of (Gain)/LossRecognized | |||
|---|---|---|---|
| Location of (Gain)/Loss Recognized in the Condensed Consolidated Statement of Operations · Three Months Ended June 30, | |||
| 2025 · 2024 | |||
| Derivatives not designated as hedges: · (Dollars in thousands) | |||
| Foreign currency derivatives | Cost of goods sold | $(292) | $(170) |
| Amount of (Gain)/LossRecognized | |||
| Location of (Gain)/Loss Recognized in the Condensed Consolidated Statement of Operations · Six Months Ended June 30, | |||
| 2025 · 2024 | |||
| Derivatives not designated as hedges: | (Dollars in thousands) | ||
| Foreign currency derivatives | Cost of goods sold | $(528) | $(43) |
The following table summarizes the fair value of our outstanding derivatives not designated as hedges (on a gross basis) and balance sheet classification as of June 30, 2025 and December 31, 2024:
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Fair Value | Fair Value | |
| (Dollars in thousands) | ||
| Prepaid and other current assets | ||
| Foreign currency derivatives | $259 | $296 |
| Other accrued liabilities | ||
| Foreign currency derivatives | (86) | (248) |
| Net asset | $173 | $48 |
(11)Accumulated Other Comprehensive Loss
The balance in our Accumulated other comprehensive loss is set forth in the following table:
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Dollars in thousands) | ||
| Foreign currency translation adjustments, net of tax | $(8,996) | $(43,573) |
| Foreign currency derivatives, net of tax | 132 | 214 |
| Total accumulated other comprehensive loss | $(8,864) | $(43,359) |
(12)Loss per Share
The following table presents a reconciliation of the numerator and denominator of basic and diluted loss per share for the three and six months ended June 30, 2025 and 2024, respectively:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Dollars in thousands, except per share amounts) | ||||
| Numerator for basic and diluted loss per share: | ||||
| Net loss | $(86,886) | $(14,752) | $(126,237) | $(45,621) |
| Denominator: | ||||
| Weighted average common shares outstanding for basic calculation | 259,183,478 | 257,772,069 | 258,779,643 | 257,587,613 |
| Weighted average common shares outstanding for diluted calculation | 259,183,478 | 257,772,069 | 258,779,643 | 257,587,613 |
| Basic loss per share | $(0.34) | $(0.06) | $(0.49) | $(0.18) |
| Diluted loss per share | $(0.34) | $(0.06) | $(0.49) | $(0.18) |
Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is calculated by dividing net loss by the sum of the weighted average number of common shares outstanding plus the additional common shares that would have been outstanding if potentially dilutive securities had been issued.
The weighted average common shares outstanding for the diluted loss per share calculation for the three and six months ended June 30, 2025 excludes the dilutive effect of approximately 289,651 shares and 281,620 shares, respectively, and 2,543 shares and 1,490 shares for the three and six months ended June 30, 2024, respectively, primarily related to restricted stock units (“RSUs”), as their inclusion would have been anti-dilutive due to the Company’s net loss.
Additionally, the weighted average common shares outstanding for the diluted loss per share calculation excludes consideration of 7,440,245 and 6,704,650 equivalent shares for the three and six months ended June 30, 2025, respectively, and 5,671,092 and 4,574,726 equivalent shares for the three and six months ended June 30, 2024, respectively, as their effect would have been anti-dilutive.
(13)Stock-Based Compensation
The Human Resources and Compensation Committee of our Board of Directors granted 3,680,476 RSUs and 1,702,363 performance-based restricted stock units (“PSUs”) to our employees during the first six months of 2025 under our Omnibus Equity Incentive Plan. Our electing non-employee directors received 297,901 deferred share units (“DSUs”) and 953,332 deferred RSUs (“DRSUs”) during the six months ended June 30, 2025 under our Omnibus Equity Incentive Plan.
We measure the fair value of grants of RSUs, DSUs and DRSUs based on the closing market price of a share of our common stock on the date of the grant (or if the market is not open for trading on such date, the immediately preceding day on which the market is open for trading). The weighted average fair value per share was $1.19 for RSUs granted to employees and $0.92 and $0.71, respectively, for DSUs and DRSUs granted to non-employee directors during the six months ended June 30, 2025.
We measure the fair value of grants of PSUs using a Monte Carlo valuation. The weighted average fair value of the PSUs granted in the first six months of 2025 was $0.61 per share and will be expensed over a vesting period ofthree years. The final payout to holders of PSUs will be based upon the Company’s total shareholder return relative to a peer group’s performance measured at the end of each performance period. The final payout for PSUs granted in 2025 is subject to a 3.5x value cap.
In the three months ended June 30, 2025 and 2024, we recognized $1.8 million and $1.6 million, respectively, of stock-based compensation expense. The majority of the expense, $1.6 million and $1.4 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold.
In the six months ended June 30, 2025 and 2024, we recognized $2.4 million and $2.6 million, respectively, of stock-based compensation expense. The majority of the expense, $1.9 million and $2.2 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of goods sold.
As of June 30, 2025, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $10.8 million and is expected to be recognized over the remaining vesting period of the respective grants.
(14)Supplementary Balance Sheet Detail
Supplier Finance Program (“SFP”) Obligations
GrafTech Mexico S.A. de C.V. (“GrafTech Mexico”) participates in an electronic vendor voucher payment program supported by the Mexican Government through one of its national banks, whereby suppliers can factor their invoices through a financial intermediary. This program gives GrafTech Mexico’s suppliers the option to settle trade receivables by obtaining payment from the financial intermediary prior to the invoice due date for a discounted amount. GrafTech Mexico’s responsibility is limited to making payment on the terms originally negotiated with its supplier, regardless of whether the supplier elects to receive early payment. The range of payment terms GrafTech Mexico negotiates with its suppliers is consistent, irrespective of whether a supplier participates in the program.
As of June 30, 2025 and December 31, 2024, $4.8 million and $5.6 million, respectively, of SFP obligations were included in accounts payable on the Condensed Consolidated Balance Sheets and upon settlement, are reflected as cash flow from operating activities in the Condensed Consolidated Statements of Cash Flows.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.